@article{a63b385eb5994ef8ae2067648b307576,
title = "Patient satisfaction with treatment outcomes after surgery and/or radiotherapy for spinal metastases",
abstract = "Background: Patient satisfaction is infrequently investigated despite its importance in assessing efficacy and patient comprehension. The purpose of this study was to investigate patient satisfaction with treatment outcomes after surgery and/or radiotherapy for spinal metastases and to evaluate how health-related quality of life (HRQOL) is related to patient satisfaction. Methods: Patients with spinal metastases treated with surgery and/or radiotherapy were enrolled in a prospective, international, observational study. Demographic, histologic, treatment, and HRQOL data were collected. HRQOL was evaluated with the Numeric Rating Scale pain score, the 3-level version of the EuroQol 5-Dimension (EQ-5D-3L) instrument, and the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ2.0). Patient satisfaction was derived from the SOSGOQ2.0 at 6, 12, and 26 weeks after treatment. Patients were classified as satisfied, neutral, or dissatisfied. Results: Twelve weeks after treatment, 183 of the surgically treated patients (84%) were satisfied, and only 11 (5%) were dissatisfied; in contrast, 101 of the patients treated with radiotherapy alone (77%) were satisfied, and only 7 (5%) were dissatisfied. Significant improvements in pain, physical function, mental health, social function, leg function, and EQ-5D were associated with satisfaction after surgery. Satisfaction after radiotherapy was associated with significant improvements in pain, mental health, and overall SOSGOQ2.0 scores. Dissatisfaction after treatment was associated with lower baseline values for leg strength and lower social functioning scores for surgically treated patients and with lower social functioning scores and being single for patients treated with radiotherapy. Conclusions: High levels of satisfaction with treatment outcomes are observed after surgery and/or radiotherapy for spinal metastases. Posttreatment satisfaction is associated with significant improvements in pain and different dimensions of HRQOL.",
keywords = "metastases, patient-reported outcomes, quality of life, radiotherapy, satisfaction, spine, surgery",
author = "{for the AOSpine Knowledge Forum Tumor} and Versteeg, {Anne L.} and Arjun Sahgal and Norio Kawahara and Rhines, {Laurence D.} and Sciubba, {Daniel M.} and Weber, {Michael H.} and {\'A}ron Lazary and Fehlings, {Michael G.} and Schuster, {James M.} and Clarke, {Michelle J.} and Arnold, {Paul M.} and Stefano Boriani and Chetan Bettegowda and Gokaslan, {Ziya L.} and Fisher, {Charles G.}",
note = "Funding Information: This study was organized and funded by AOSpine International through the AOSpine Knowledge Forum Tumor, a focused group of international spine oncology experts acting on behalf of AOSpine. Study support was provided directly through the AOSpine Research Department and the AO Clinical Investigation and Documentation Unit. A research grant was also received from the Orthopaedic Research and Education Foundation. Funding Information: Anne L. Versteeg reports consulting and travel accommodations from AOSpine International. Arjun Sahgal reports past educational seminars with Elekta AB, BrainLAB, Medtronic Kyphon, Accuray, Inc, and Varian Medical Systems; a research grant from Elekta AB; advisory/consulting roles with AbbVie, Merck, Roche, VieCure, and BrainLAB; travel accommodations and expenses from Elekta, BrainLAB, and Varian; and membership in the Elekta MR Linac Research Consortium and the International Stereotactic Radiosurgery Society. Laurence D. Rhines reports educational commitments to Stryker outside the submitted work. Daniel M. Sciubba reports consulting for and royalties from Medtronic, DePuy Synthes, Stryker, Nuvasive, Globus, Baxter, and K2M outside the submitted work. Paul M. Arnold reports travel accommodations and expenses from AOSpine North America; intellectual property rights and interests, equity, and a position of responsibility in Evoke Medical; equity in Z‐Plasty; consulting fees from Stryker Orthopaedics, Ulrich, SpineGuard, and InVivo Therapeutics; and consulting fees, travel accommodations, and expenses from Stryker Spine, Spinewave, Medtronic outside the submitted work. Stefano Boriani reports educational commitments to K2M Stryker and Nuvasive outside the submitted work. Chetan Bettegowda reports acting as a consultant for DePuy Synthes outside the submitted work. Ziya L. Gokaslan reports research support from AOSpine North America and stock ownership in Spinal Kinetics outside the submitted work. Charles G. Fisher reports consulting for and royalties from Medtronic, personal fees from Nuvasive, research grants from the Orthopaedic Research and Education Foundation, and fellowship support paid to his institution from AOSpine and Medtronic outside the submitted work. The other authors made no disclosures. Publisher Copyright: {\textcopyright} 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society",
year = "2019",
month = dec,
day = "1",
doi = "10.1002/cncr.32465",
language = "English (US)",
volume = "125",
pages = "4269--4277",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",
}